Biogen (BIIB) PT Raised to $420.00 at Nomura

Cornelia Mascio
Gennaio 7, 2018

Primecap Management Company, which manages about $87.86 billion and $120.82B US Long portfolio, upped its stake in Beigene Ltd Adr by 166,667 shares to 292,005 shares, valued at $30.21M in 2017Q3, according to the filing. Primecap Management Company sold 178,487 shares as the company's stock declined 13.45% while stock markets rallied. Institutional & Family Asset Management LLC grew its stake in shares of Biogen by 19.9% in the third quarter. Vanguard Group Inc. now owns 14,534,827 shares of the biotechnology company's stock worth $3,944,171,000 after purchasing an additional 182,337 shares in the last quarter. It also reduced its holding in Exlservice Holdings Inc (NASDAQ:EXLS) by 8,700 shares in the quarter, leaving it with 1.12 million shares, and cut its stake in Kraton Corporation (NYSE:KRA). Nomura now has a buy rating on the biotechnology company's stock. State Street Corp raised its holdings in shares of Biogen by 1.5% in the 2nd quarter. People s United Financial Inc. now owns 2,269 shares of the biotechnology company's stock valued at $616,000 after purchasing an additional 25 shares during the last quarter. Parametric Portfolio Associates LLC grew its stake in shares of Biogen by 3.4% in the third quarter. LLC now owns 425 shares of the biotechnology company's stock valued at $133,000 after acquiring an additional 195 shares during the period.

Biogen (NASDAQ:BIIB) opened at $342.49 on Monday. Biogen Inc has a 52-week low of $244.28 and a 52-week high of $348.84. The firm has a market capitalization of $71,900.03, a PE ratio of 21.00, a P/E/G ratio of 1.96 and a beta of 0.72. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.19 and a quick ratio of 1.90. Biogen Inc. (NASDAQ:BIIB) has risen 4.94% since January 6, 2017 and is uptrending. The biotechnology company reported $6.31 EPS for the quarter, beating analysts' consensus estimates of $5.70 by $0.61. Biogen had a net margin of 32.34% and a return on equity of 38.48%. The company had revenue of $3.08 billion during the quarter, compared to analysts' expectations of $3.05 billion. During the same quarter in the prior year, the company earned $5.19 EPS. During the same period previous year, the business earned $5.19 EPS. (NASDAQ:BIIB). Dekabank Deutsche Girozentrale reported 217,152 shares or 0.5% of all its holdings. Jefferies maintained the shares of BIIB in report on Monday, June 12 with "Hold" rating. Raymond James initiated the stock with "Strong-Buy" rating in Tuesday, September 1 report. Ten research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has issued a strong buy rating to the company. Biogen presently has a consensus rating of "Buy" and a consensus price target of $350.13. Canaccord Genuity set a $340.00 price objective on shares of Biogen and gave the company a "hold" rating in a research report on Wednesday, December 20th. Finally, Stifel Nicolaus raised shares of Biogen from a "hold" rating to a "buy" rating and boosted their price objective for the company from $300.00 to $415.00 in a research report on Tuesday, October 17th.

Among 4 analysts covering Kennedy-Wilson Holdings (NYSE:KW), 2 have Buy rating, 0 Sell and 2 Hold. Goldman Sachs has "Buy" rating and $376.0 target. The stock was acquired at an average price of $317.36 per share, for a total transaction of $9,520,800.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michel Vounatsos acquired 780 shares of Biogen stock in a transaction that occurred on Saturday, December 29th. The stock was purchased at an average cost of $320.55 per share, for a total transaction of $250,029.00. Northwestern Mutual Wealth Management Co. now owns 4,504 shares of the biotechnology company's stock valued at $1,089,000 after buying an additional 1,220 shares during the period. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 31,560 shares of company stock worth $10,020,858. Following the completion of the sale, the director now directly owns 22,078 shares in the company, valued at $6,521,620.42.

TRADEMARK VIOLATION WARNING: This report was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another website, it was illegally copied and republished in violation of U.S. and global copyright & trademark laws. State Of Alaska Department Of Revenue invested 0.03% of its portfolio in Biogen Inc.

Biogen Inc is a biopharmaceutical company. The firm offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis; FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy.

Want to see what other hedge funds are holding BIIB?

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE